Trial Profile
A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary) ; Meningococcal vaccine groups A B C Y W-135 conjugate
- Indications Ebola virus infections
- Focus Adverse reactions; Registrational
- Acronyms EBOVAC-Salone
- Sponsors Janssen Vaccines and Prevention B.V
- 30 May 2022 Results of sub study of Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children, published in the Clinical Infectious Diseases
- 01 Jan 2022 Protocol of study has been amended to change primary endpoint vaccine effectiveness and study design, after Ebola virus disease outbreak in Sierra Leone declined
- 01 Jan 2022 Results (n=443 ), published in The Lancet Infectious Diseases